Login
← Go Back
Biocon
BIOCON · Pharma > Pharmaceuticals & Drugs · Chairman: Kiran Mazumdar-Shaw · MD: Siddharth Mittal · Listing date: April 8, 2004 · Employees: 13500 · Bangalore · http://www.biocon.com
Stock Price vs Company Growth
1d
1.6%
1w
0.1%
1m
7.0%
3m
7.1%
6m
1.6%
1y
6.6%
5y
2.6%
10y
14.5%
all
14.2%
🤔 How to analyze this graph?
Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price
₹ 350 1.6%
338
403
Company Overview
Sales
16,827 Cr
Growth: 12.6%
Profit after Tax
584 Cr
Growth: 30.6%
Large Cap
56,805 Cr
P/E: 72.3x
Industry P/E: 28.0x
Fundamentals
Sales (Cr) ₹ 16,827
Growth 12.6%
EBITDA 20.8%
P/S 3.4x
Dividend 0.1%
P/E 72.3x
Book Value ₹ 136
PEG Ratio 5.7x
ROE 2.7%
P/B 2.6x
Shareholding Pattern
Institutions
Life Insurance Corporation Of India (Lic)
4.11 %
Ahan- I Ltd
1.66 %
Qualified Institutional Buyer
0.61 %
Promoters
Kiran Mazumdar Shaw
39.62 %
Glentec International
19.76 %
John Mccallum Marshall Shaw
0.7 %
Ravi Rasendra Mazumdar
0.4 %
Yamini R Mazumdar
0.11 %
Others
Arun Suresh Chandavarkar
1.1 %
Beneficial Holdings Under Mgt-4
0.46 %
Iepf
0.01 %
Increase    Decrease    No change
Company Profile Detailed
The company is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the US and Europe.
Belongs to (37 Indices) view more
Investors (373)
mahesh.g...
syed.sal...
vedavyas...
Followers (42)
kiran198...
deepak
nitin2